|
Briefing
|
- World’s first – Chinese scientists were first to conduct trial of CRISPR gene editing on humans after injecting edited immune cells to an adult human with lung cancer
- CRISPR-edited – Turned off protein called PD-1 that slows immune response from patient’s immune cells using CRISPR gene editing, allowing body to attack and destroy cancer cells
- Competition with U.S. – Experiment can trigger biomedical race with U.S. which is planning similar trials targeted to cancer diseases scheduled early next year
- Future plans – Continue testing CRISPR editing on 10 patients and consider conducting three more clinical trials in March 2017 for bladder, prostate and renal cell cancers
|
|
Accelerator
|
|
|
Sector
|
Healthcare/Health Sciences
|
|
Organization
|
Sichuan University
|
|
Source
|
|
|
Original Publication Date
|
November 15, 2016
|
